Could a Simple Blood Test Predict Preeclampsia?

Preeclampsia, a serious pregnancy complication characterized by high blood pressure and organ damage, affects 3% to 7% of all pregnancies. This condition can lead to premature birth, slow fetal growth, and even maternal mortality. Currently, there is no reliable test to predict preeclampsia early on, making timely intervention challenging.

However, new research suggests that a simple blood test, utilizing the fibrinogen-to-albumin ratio (FAR), might hold the key to identifying pregnant women at risk for developing preeclampsia.

Study Findings

A retrospective study conducted at the Icahn School of Medicine at Mount Sinai in New York City, presented at the American Society of Anesthesiologists (ASA) annual meeting, found that FAR emerged as a strong predictor of both preeclampsia and severe preeclampsia.

Researchers analyzed data from 2,629 women who gave birth between 2018 and 2024. They found that women with a higher FAR had a significantly increased risk of developing preeclampsia, even after accounting for factors like age, race, and pre-existing conditions.

Specifically, the study reported an odds ratio (OR) of 37.38 for any preeclampsia and an OR of 18.49 for severe preeclampsia in patients with elevated FAR.

Understanding FAR

While FAR is already being studied as a potential marker for other inflammatory conditions like rheumatoid arthritis, heart disease, and stroke, this is one of the first studies to explore its application in predicting preeclampsia.

The study’s lead author, Lucy Shang, a medical student at Mount Sinai, explained, “Our study shows that FAR can be a predictive tool that gives anesthesiologists and obstetricians a new method for assessing a laboring mom’s risk of developing preeclampsia when they are admitted to the hospital.”

Next Steps and Future Research

While these findings are promising, experts emphasize the need for further research before incorporating FAR into routine prenatal care.

Dr. Carla Janzen, a maternal-fetal medicine specialist at the University of California, Los Angeles, stressed the importance of validating these findings in prospective studies, particularly among high-risk populations, including non-Hispanic Black women who are disproportionately affected by preeclampsia.

Dr. Connie Graves, another expert in maternal-fetal medicine, noted that while FAR offers potential, further research is needed to determine the specific range of FAR values that would be considered concerning and the timing of testing for optimal prediction.

The researchers agree and are currently working to analyze a larger, multi-center dataset to further investigate the potential of FAR in predicting preeclampsia.

A glimmer of hope for early detection

This study offers a glimmer of hope for earlier and more effective preeclampsia management. While more research is required, the ability to identify high-risk women through a simple blood test could revolutionize prenatal care and ultimately improve both maternal and fetal outcomes.

Learn more about preeclampsia and its risk factors by visiting the American College of Obstetricians and Gynecologists website: https://www.acog.org/womens-health/faqs/preeclampsia